Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2003-09-18
- Last Posted Date
- 2016-10-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 2035
- Registration Number
- NCT00069095
A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2003-09-18
- Last Posted Date
- 2016-04-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 627
- Registration Number
- NCT00069108
Study of Ro 205-2349 in Patients With Type 2 Diabetes Mellitus
Phase 2
Completed
- Conditions
- First Posted Date
- 2003-04-01
- Last Posted Date
- 2016-08-24
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT00057317
Study to Determine the Efficacy, Safety, Tolerability & Pharmacokinetics of RO 205-2349 in Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2003-04-01
- Last Posted Date
- 2023-04-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 190
- Registration Number
- NCT00057304
A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 208
- Registration Number
- NCT00022672
Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-04-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 5099
- Registration Number
- NCT00045032
- Locations
- 🇦🇺
Saint John of God Hospital, Geelong, Australian Capital Territory, Australia
🇦🇹Landeskrankenhaus Klagenfurt, Klagenfurt, Austria
🇧🇪Centre Hospitalier Notre Dame - Reine Fabiola, Charleroi, Belgium
Capecitabine and Irinotecan in Treating Patients With Locally Advanced, Recurrent, or Metastatic Colorectal Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-04-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 67
- Registration Number
- NCT00022698
- Locations
- 🇺🇸
Markey Cancer Center at University of Kentucky Chandler Medical Center, Lexington, Kentucky, United States
🇺🇸Eastern Connecticut Hematology and Oncology Associates, Norwich, Connecticut, United States
🇺🇸George Washington University Medical Center, Washington, District of Columbia, United States
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Phase 3
Completed
- Conditions
- First Posted Date
- 2002-11-14
- Last Posted Date
- 2017-02-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 820
- Registration Number
- NCT00048945
A Study to Assess Use of Zenapax (Daclizumab) and CellCept (Mycophenolate Mofetil) to Improve Kidney Function in Kidney Transplant Patients
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2002-10-25
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 539
- Registration Number
- NCT00048152
A Study to Evaluate the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2002-10-25
- Last Posted Date
- 2016-06-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 434
- Registration Number
- NCT00048165
© Copyright 2024. All Rights Reserved by MedPath